Select Page

EVQLV Wins Columbia Venture Competition

Apr 29, 2020 | News | 0 comments

Daniel Gigante

EVQLV is excited to announce we took first place in Columbia Engineering’s Venture Competition (CVC). We’ve included a snippet from the announcement below. If you’d like to read the official release, you can do so here.

In the Technology Challenge, avoMD and EVQLV each took first place and $20,000 in funding. avoMD, led by cofounders Joongheum Park, Yair Saperstein, and Laurence Coman, is a digital point-of-care personal assistant made for doctors by doctors. EVQLV is an artificial intelligence company focused on accelerating biologic therapies. The company was founded by Andrew Satz and Bret Averso, who aimed to leverage AI to computationally design innovative antibody candidates that can be quickly synthesized and validated. Dialetica, developing wearables for managing advanced-stage kidney failure, placed in third, winning $10,000 in funding.

We would like to give a special thanks to all fellow companies, the wonderful judges, and of course, Columbia Engineering.


Submit a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...